New Data Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) in Evaluation of Hypertension...
November 13 2018 - 8:30AM
Daxor Corporation
(NYSE MKT: DXR), an investment
company with innovative medical instrumentation and biotechnology
operations focused on blood volume measurement, today announces new
data from Duke University Medical Center that was presented
Saturday, November 10, 2018 at the American Heart Association
Scientific Sessions in Chicago, IL. The study titled “Blood Volume
and Analysis in Patients with Hypertension,” looked at the three
main components of blood in adults with hypertension; total blood
volume (TBV), red blood cell volume (RBV) and plasma volume (PV) to
test whether there is a relationship between these blood volume
parameters and standard blood pressure (SBP) and to see whether
there is a correlation with race. Blood volume parameters were
measured with Daxor’s BVA-100 and blood volumes were expressed as a
percent deviation from the patient’s ideal volumes.
Marat Fudim, M.D., lead author of the study
commented, “Our findings support the need for more detailed
analysis of blood volume type, as this could help guide
anti-hypertensive management.” The results showed that patients
with hypertension have a wide variation in TBV, RBCV and PV and
that SBP does not correlate with direct blood volume measurement.
Blacks had lower blood volume parameters compared to Non-Blacks
(p<0.001), despite higher SBP (159 mmHg, SD +/- 98 vs.142 mmHg,
SD +/- 72). “Volume management is an essential component of
anti-hypertensive therapy -- progressive hypertension often leads
to stroke, heart failure and kidney failure, taking a tremendous
toll on the quality of life for millions of adults every year,”
said Michael Feldschuh, CEO of Daxor Corporation. This study adds
to the wide body of evidence that proves blood volume heterogeneity
is common in these medical conditions but not properly detected
through conventional pressure metrics. The BVA-100 provides a
simple, rapid, and accurate means to directly measure blood volume
to help physicians best individualize treatment to ensure better
patient outcomes and improve their quality of life.”
About Daxor Corporation
Daxor Corporation is an innovative medical
instrumentation and biotechnology company. We manufacture the
BVA-100 Blood Volume Analyzer, the only clinically available, rapid
and accurate diagnostic which provides rapid direct measurement of
a patient’s blood volume. We believe that the BVA-100 Blood Volume
Analyzer has the potential to transform therapy in a broad range of
surgical and medical conditions. It is our goal, working in
conjunction with hospitals and clinics, to achieve that
possibility. Ultimately the company’s mission is to help hospitals
and physicians incorporate Daxor’s BVA-100 diagnostic to
significantly improve the quality of patient care. For more
information please visit our website at http://www.daxor.com.
Forward-Looking Statements
Certain statements in this release may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, including without
limitation, statements regarding the impact of hiring sales staff
and expansion of our distribution channels. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risks associated with
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with
and benefits from acquired businesses, and additional other risks
and uncertainties described in our filings with the SEC.
Forward-looking statements speak only as of the date when made.
Daxor does not assume any obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information:
Investor Relations Contact:Bret ShapiroSr. Managing PartnerCORE
IR561-479-8566brets@coreir.com
Daxor (AMEX:DXR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Daxor (AMEX:DXR)
Historical Stock Chart
From Sep 2023 to Sep 2024